News Boehringer looks to cancer immunotherapy combinations BI developing combinations with its own checkpoint inhibitors
News Boosted by new drugs, Boehringer shrugs off patent expiry BI boosted by new diabetes and respiratory drugs.
News Real world data will help AZ's Farxiga in cardio battle AZ hopes data will boost sales of its Farxiga.
Views & Analysis Precision medicine and data science: the ‘new normal’ for dr... Balancing innovation and huge unmet patient need with burgeoning cost constraints.
News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News Lilly plans Q1 2027 filing for obesity triple retatrutide Armed with new pivotal trial results, Eli Lilly is preparing to file for approval of its triple-acting weight-loss therapy, retatrutide, next year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
